BD names Vitor Roque as chief financial officer
Get Alerts BDX Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: -11.1%
Join SI Premium – FREE
BD (NYSE: BDX) appointed Vitor Roque as executive vice president and chief financial officer, effective May 7. Roque had served as interim CFO since December 2025.
Roque brings more than 25 years of experience at the medical technology company, most recently serving as senior vice president of Finance and Corporate Financial Planning and Analysis. During his interim CFO tenure, he led the global finance function and helped complete the separation of BD's Biosciences & Diagnostic Solutions business.
"Following a comprehensive search process, it was clear that Vitor is the right leader to serve as BD's next CFO," said Tom Polen, chairman, CEO and president of BD. "Vitor brings an unmatched understanding of our business, a proven ability to translate strategy into performance and the discipline to drive consistent execution at scale."
The Franklin Lakes, New Jersey-based company stated that Roque's experience spans finance and operations roles across business units, regions and manufacturing. His background includes work in multiple countries, providing global perspective on BD's operations.
"After more than two decades with the company, I see tremendous opportunity ahead," Roque said. "BD is well positioned to drive consistent performance, deliver durable growth and increase shareholder value creation."
BD describes itself as one of the world's largest medical technology companies, with more than 60,000 employees operating globally. The company develops medical devices, connected care solutions and biopharma systems.
You May Also Be Interested In
- Circle board member resigns after nearly 13 years of service
- Starbucks designates Val Bauduin as principal accounting officer
- Adobe CFO Dan Durn to depart company in June 2026
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share